Alzheimer’s disease (AD) is a neurodegenerative disorder that severely jeopardizes the health of aging populations
all over the world. According to the amyloid cascade hypothesis, the pathological progression of AD is associated
with the formation of amyloid plaques in the brain, resulting from the aggregation of amyloid-β (Aβ) peptides. Over the
past few years, vast efforts have been dedicated to the development of amyloid probes and inhibitors for the diagnosis and
effective treatment of AD. We review here recent advancements in luminescent probes for the detection of Aβ peptide and
fibrils, and the current development of small molecule inhibitors of Aβ aggregation. We also highlight the key features in
each specific example, as well as review new ideas and strategies that are crucial for researchers in this field.
Keywords: Aggregation inhibitor, Alzheimer’s disease, beta-amyloid, luminescent probe, therapeutics agents, cholinergic neurons, trauma, amyloid cascade.
Rights & PermissionsPrintExport
Published on: 02 August, 2012
Page: [830 - 843]